secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2025-10-20T23:59:59+00:00
Accession:  0001193125-25-243046
Event type: other
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Pharma reports CRB-701 Phase 1/2 ORR 47.6% HNSCC, 55.6% mUC at ESMO25
----------------------------------------------------------------------------

- 3.6 mg/kg dose: ORR 47.6% in HNSCC (n=21), 37.5% in cervical cancer (n=16), 55.6% in mUC (n=9).
- No grade 4/5 treatment-related AEs; low discontinuation rate (6.0%) and peripheral neuropathy (8.4% Grade 1/2).
- Responses seen regardless of Nectin-4, HPV, or PD-L1 status; median prior therapies = 3.
- Company plans FDA meeting in 2025 and registrational studies by mid-2026.
- Data presented at ESMO25 from 167 patients; 122 evaluable for efficacy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000119312525243046/0001193125-25-243046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000119312525243046/crbp-20251018.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-243046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer